Related Experiment Video
Updated: Apr 21, 2026
Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
Published on: November 17, 2023
Overcoming tumor heterogeneity in the molecular diagnosis of urological cancers
Michael J Donovan1, Carlos Cordon-Cardo
1Department of Pathology, Icahn School of Medicine, 1468 Madison Avenue, New York City, NY 10029, USA.
Abstract:
Our understanding of tumor heterogeneity and impact on treatment response is still in its infancy, presenting significant challenges to the molecular pathologist, treating physician and ultimately for the patient. Given that tumor recurrence due to treatment resistance is the most common cause of cancer death, there remains a critical unmet need to change the current paradigm. The mechanisms which underlie tumor heterogeneity can be broadly divided into genomic instability and non-mutational processes, including stochastic variations in cellular responses, modulation by tumor microenvironment and or phenotypic/ functional plasticity relating to cancer stem cells. We believe that these biological mechanisms are not mutually exclusive and emphasize the need for more suitable methodologies to exploit the spatiotemporal patterns of intratumoral heterogeneity using novel approaches such as quantitative tissue-based biomarker assessment and systemic fluid analytics. Generating a comprehensive patient-centric phenotypic disease profile should generate a 'codex' which can be employed to change the current treatment decision process.
Insights
Understanding tumor heterogeneity is crucial for improving cancer treatment. New methods analyzing tissue and fluid biomarkers can create patient profiles to combat treatment resistance and recurrence.
Area of Science:
- Oncology
- Molecular Pathology
- Cancer Biology
Background:
- Tumor heterogeneity significantly challenges cancer treatment and patient outcomes.
- Treatment resistance leading to tumor recurrence is a primary cause of cancer mortality.
- Current understanding of tumor heterogeneity and its impact on treatment response is limited.
Purpose of the Study:
- To highlight the need for improved methodologies to address tumor heterogeneity.
- To emphasize the importance of spatiotemporal patterns in intratumoral heterogeneity.
- To propose a new paradigm for patient-centric cancer treatment decision-making.
Main Methods:
- Investigating genomic instability and non-mutational processes driving tumor heterogeneity.
- Exploring stochastic cellular variations, tumor microenvironment modulation, and cancer stem cell plasticity.
- Utilizing quantitative tissue-based biomarker assessment and systemic fluid analytics.
Main Results:
- Tumor heterogeneity arises from both genomic and non-mutational mechanisms.
- Spatiotemporal analysis of intratumoral heterogeneity requires novel assessment approaches.
- A comprehensive patient-centric phenotypic disease profile can guide treatment decisions.
Conclusions:
- Addressing tumor heterogeneity is critical for overcoming treatment resistance.
- Novel methodologies integrating tissue and fluid analyses are needed.
- Developing patient-specific 'codex' profiles can revolutionize cancer care.
